James T. Parsons
James T. Parsons's purchase track record
James T. Parsons has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2026 | ONCY | $10K | -20.8% | -20.8% | +12.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
Transaction History
| ONCY | ▲ Buy | Open Market | 10,000 | $10K | 3/11/2026 | View on chart |
| DMAC | ▲ Buy | Grant | 10,095 | $85K | 1/2/2026 | View on chart |
| DMAC | ▲ Buy | Option Exercise | 12,000 | $26K | 11/21/2025 | View on chart |
| DMAC | ▲ Buy | Grant | 15,917 | $85K | 1/2/2025 | View on chart |
| DMAC | ▲ Buy | Grant | 21,428 | $60K | 1/2/2024 | View on chart |
| DMAC | ▲ Buy | Grant | 16,773 | $60K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Oncolytics Biotech Activates All REO 033 Trial Facilities
Oncolytics Biotech has activated all planned facilities for Part A of its REO 033 trial in colorectal cancer. The company reported accelerating enrollment, with multiple participants admitted to the study. This progress occurs as the broader KRAS inhibitor market is projected to grow significantly in the coming years.
Oncolytics Biotech Activates All REO 033 Trial Facilities. Oncolytics Biotech has activated all planned facilities for Part A of its REO 033 trial in colorectal cancer. The company reported accelerating enrollment, with multiple participants admitted to the study. This progress occurs as the broader KRAS inhibitor market is projected to grow significantly in the coming years.